Stock Research: Nektar

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Nektar

NasdaqGS:NKTR US6402681083
13
  • Value
    70
  • Growth
    18
  • Safety
    Safety
    6
  • Combined
    9
  • Sentiment
    50
  • 360° View
    360° View
    13
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Nektar Therapeutics is a clinical-stage biotechnology company developing treatments for immunological dysfunction in autoimmune and chronic inflammatory diseases and oncology. The company focuses on medicines targeting biological pathways to stimulate the immune response to fight cancer. Nektar Therapeutics operates in the biotechnology industry. In the last fiscal year, the company had $400 million in market cap, profits of $68 million, revenue of $98 million, and 61 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 13 (better than 13% compared with alternatives), overall professional sentiment and financial characteristics for the stock Nektar are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Nektar. The consolidated Sentiment Rank has a good rank of 50, which means that professional investors are more optimistic about the stock than for 50% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 70 or better than 70% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 6, meaning that the share price of Nektar is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 18. ...read more

more
Index
NASDAQ
D.J. US Pharmaceutical
S&P MIDCAP
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
18 73 39 75
Safety
Safety
70 93 94 77
Sentiment
50 16 4 20
360° View
360° View
13 49 60 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
74 17 1 29
Opinions Change
63 50 50 50
Pro Holdings
n/a 70 19 78
Market Pulse
9 15 13 14
Sentiment
50 16 4 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
18 73 39 75
Safety Safety
70 93 94 77
Combined
9 81 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
81 81 81 8
Price vs. Earnings (P/E)
5 49 74 14
Price vs. Book (P/B)
8 28 81 42
Dividend Yield
1 1 1 1
Value
6 22 77 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
10 4 6 97
Profit Growth
14 71 66 25
Capital Growth
4 85 100 85
Stock Returns
100 87 5 43
Growth
18 73 39 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
40 92 100 71
Liquidity
25 25 22 11
Safety Safety
70 93 94 77

Similar Stocks

Discover high‑ranked alternatives to Nektar and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

PriceSmart

NasdaqGS:PSMT
Country: USA
Industry: Hypermarkets, Super Centers
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.